FDA Biocompatibility Guidance Adds Nanotech, Absorbability Test Tips
This article was originally published in The Gray Sheet
Executive Summary
A June 15 FDA final guidance on biological evaluation of devices adds new sections on biocompatibility testing compared to the 2013 draft version, including a risk-based approach to biocompatibility testing, as well as test article preparation recommendations for devices with submicron/nanotech components, in situ polymerizing or absorbable materials, and tips for chemical testing.
You may also be interested in...
Nanotech: FDA Seeks Input On Needed Device Tests, Defends Budget Request
FDA will seek advice next month on the types of pre-clinical tests it should require for devices that incorporate nanotechnology
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.